Tag: KDC-MN-361

  • Domagrozumab

    Anti-myostatin monoclonal antibody

    A humanized anti-myostatin monoclonal antibody developed at Pfizer for Duchenne muscular dystrophy; phase 2 trial failed.

    Abstract

    Domagrozumab (PF-06252616; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized anti-myostatin monoclonal antibody developed at Pfizer. The compound is selective for myostatin (GDF-8) with high affinity, designed to neutralize circulating myostatin in Duchenne muscular dystrophy. Phase 2 trial in DMD (2018) demonstrated muscle mass increases on MRI but no significant improvement in functional endpoints (6-minute walk test, North Star Ambulatory Assessment); Pfizer discontinued development. The trial result reinforced a broader concern about myostatin inhibition in DMD: muscle mass gains may not translate to clinical benefit if the underlying dystrophin deficiency continues to cause fiber damage. Used as a research compound for selective myostatin neutralization in DMD context.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.